Use

The test is useful for therapeutic drug monitoring of adalimumab (ADL), particularly in cases of loss of response or hypersensitivity reactions. It aids in the evaluation of patients for secondary loss of response, primary nonresponse, reintroduction after a drug holiday, and monitoring during therapy such as in inflammatory bowel disease or autoimmune conditions. Monitoring can assist in distinguishing between pharmacokinetic failure and immunogenicity, enabling appropriate adjustments like dose escalation or switching therapies, thereby improving treatment cost-effectiveness and patient outcomes.